Mesothelioma/Tremelimumab (#521)
Laufzeit: 01.01.2013 - 31.12.2014
imported
Kurzfassung
A phase 2, randomized, double-blind study comparing Tremelimumab to placebo in second- or third-line treatment of subjects with unresectable pleural or peritoneal malignant mesothelioma
